Dr. Jamal G. Misleh

Hematology | Oncology | Internal Medicine

Christiana Care Health System

651 North Broad Street, Suite 406,

Middletown, DE

On Staff At

Christiana Care Health System

651 North Broad Street, Suite 406,

Middletown, DE

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jamal Misleh is a Hematologist and an Internal Medicine provider in Middletown, Delaware. Dr. Misleh is rated as an Experienced provider by MediFind in the treatment of Familial Benign Copper Deficiency. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Neuroendocrine Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Miami School Of Medicine

Residency

University of Pennsylvania Hospital

Specialties

Hematology

Oncology

Internal Medicine

Licenses

Internal Medicine in DE

Fellowships

Univ of Maryland -St. Joe Medical Center

Hospital Affiliations

Bayhealth Hospital, Sussex Campus

Bayhealth Medical Center, Kent Campus

Christiana Hospital

Beebe Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

Medical Oncology Hematology Consultants
651 North Broad Street, Suite 406, Middletown, DE 19709

Call: 302-366-1200

Other Locations

Medical Oncology Hematology Consultants
4701 Ogletown Stanton Road, Helen F Graham Cancer Center, Suite 3400, Newark, DE 19713

Call: 302-366-1200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: December 16, 2025

Intervention Type: Drug

Study Drugs: TJ004309, Atezolizumab

Study Phase: Phase 2

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Enrollment Status: Completed

Publish Date: December 12, 2025

Intervention Type: Drug

Study Drugs: ladiratuzumab vedotin, Pembrolizumab

Study Phase: Phase 1/Phase 2

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

Enrollment Status: Active_not_recruiting

Publish Date: December 10, 2025

Intervention Type: Drug

Study Drugs: tucatinib, T-DM1

Study Phase: Phase 3

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Enrollment Status: Active_not_recruiting

Publish Date: November 14, 2025

Intervention Type: Drug

Study Drug: ARX788

Study Phase: Phase 2

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma

Enrollment Status: Active_not_recruiting

Publish Date: September 11, 2025

Intervention Type: Combination product, Procedure, Drug

Study Drugs: IGV-001 Cell Immunotherapy, Temozolomide

Study Phase: Phase 2

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

Enrollment Status: Terminated

Publish Date: July 15, 2025

Intervention Type: Drug

Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Enrollment Status: Active_not_recruiting

Publish Date: May 28, 2025

Intervention Type: Drug

Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Enrollment Status: Active_not_recruiting

Publish Date: April 20, 2025

Intervention Type: Drug

Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab

Study Phase: Phase 3

Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Enrollment Status: Terminated

Publish Date: June 14, 2024

Intervention Type: Drug

Study Drugs: TAK-981, Rituximab

Study Phase: Phase 1/Phase 2

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Enrollment Status: Terminated

Publish Date: June 04, 2024

Intervention Type: Drug

Study Phase: Phase 2

P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib

Enrollment Status: Terminated

Publish Date: February 26, 2024

Intervention Type: Drug

Study Drugs: Enobosarm, Abemaciclib, Non-steroidal AI or steroidal AI or Fulvestrant

Study Phase: Phase 3

A Phase 1b/2, Multicenter, Single Arm Study of RBN-2397 in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (SCCL)

Enrollment Status: Unknown

Publish Date: July 03, 2023

Intervention Type: Drug

Study Drug: RBN-2397

Study Phase: Phase 1/Phase 2

A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer

Enrollment Status: Terminated

Publish Date: April 10, 2023

Intervention Type: Drug

Study Drug: Bintrafusp alfa

Study Phase: Phase 2

Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)

Enrollment Status: Terminated

Publish Date: March 13, 2023

A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors

Enrollment Status: Withdrawn

Publish Date: September 06, 2019

Intervention Type: Drug

Study Phase: Phase 4

View 14 Less Clinical Trials

19 Total Publications

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer

Published: July 04, 2025

View All 19 Publications

Similar Doctors

Experienced in Familial Benign Copper Deficiency

Dr. Margaret T. Kasner

Hematology Oncology | Oncology | Palliative Medicine

Experienced in Familial Benign Copper Deficiency

Dr. Margaret T. Kasner

Hematology Oncology | Oncology | Palliative Medicine

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14,

Philadelphia, PA

(32.9 miles away)

215-955-8874

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Margaret Kasner is an Oncologist and a Palliative Medicine provider in Philadelphia, Pennsylvania. Dr. Kasner is rated as a Distinguished provider by MediFind in the treatment of Familial Benign Copper Deficiency. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is currently accepting new patients.

Experienced in Familial Benign Copper Deficiency

Dr. Chetan S. Jeurkar

Internal Medicine | Oncology

Experienced in Familial Benign Copper Deficiency

Dr. Chetan S. Jeurkar

Internal Medicine | Oncology

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14,

Philadelphia, PA

(32.9 miles away)

215-955-8874

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Chetan Jeurkar is a primary care provider, practicing in Oncologist in Philadelphia, Pennsylvania. Dr. Jeurkar is rated as an Experienced provider by MediFind in the treatment of Familial Benign Copper Deficiency. His top areas of expertise are Familial Benign Copper Deficiency, Acute Myeloid Leukemia (AML), Leukemia, and Acute Myeloblastic Leukemia with Maturation. Dr. Jeurkar is currently accepting new patients.

VIEW MORE FAMILIAL BENIGN COPPER DEFICIENCY DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Misleh's expertise for a condition

ConditionClose